低剂量GLP-1疗法减轻了HFpEF中的病态心脏和肝脏重塑,独立于体重减轻
Mahmoud H Elbatreek1,2, Zhen Li3, Xiaoman Yu3
1Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
bioRxiv : the preprint server for biology
|November 19, 2025
概括
在小鼠中,低剂量塞马格卢提德改善了心力衰竭与保存的喷射分数 (HFpEF),独立于体重减轻. 这表明GLP-1受体激动剂 (GLP-1RAs) 对心脏和肝脏功能有直接的益处.
科学领域:
- 心血管医学 心血管医学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭带来了重大的治疗挑战.
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 是有前途的,其益处通常归因于减肥.
- 在HFpEF中GLP-1RAs的体重减轻独立的影响需要进一步调查.
研究的目的:
- 为了研究低剂量GLP-1RA治疗在严重心脏代谢HFpEF的动物模型中的体重减轻独立的影响.
- 通过使用多omics方法,探索GLP-1RA在HFpEF中的作用的潜在机制.
主要方法:
- 用HFpEF治疗ZSF1肥胖大鼠,使用低剂量赛马格卢提德或载体治疗16周.
- 综合评估包括心声回声,血液动力学,运动能力和心脏/肝纤维化.
- 利用单细胞RNA测序和蛋白质组学来获得机械洞察力.
主要成果:
- 低剂量塞马格卢提德显著改善了心脏功能和运动耐受性,而不会导致体重减轻.
- 减弱的心脏和肝纤维化,心脏和肝脏中的脂质含量降低.
- 多种omics显示了心脏代谢的改善,减少了亲纤维/亲缩信号,并减少了全身炎症.
结论:
- 低剂量塞马格卢提德在HFpEF中提供心脏保护性,肝脏保护性和代谢性益处,独立于减肥.
- 这些发现支持研究更低的GLP-1RA剂量用于HFpEF和其他心血管疾病,包括非肥胖个体.
相关概念视频
01:30Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
01:24Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:29Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
01:29Cardiomyopathy V: Interprofessional Care
316
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
316